Skip to content
Lepirudin
Refludan (lepirudin) is a protein pharmaceutical. Lepirudin was first approved as Refludan on 1997-03-13. It is used to treat thrombocytopenia, thromboembolism, and unstable angina in the USA. It has been approved in Europe to treat thrombocytopenia and thromboembolism. The pharmaceutical is active against prothrombin.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
thrombocytopeniaHP_0001873D013921D69.6
thromboembolismHP_0001907D013923—
unstable anginaEFO_1000985D000789I20.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AE: Direct thrombin inhibitors
— B01AE02: Lepirudin
HCPCS
Code
Description
J1945
Injection, lepirudin, 50 mg
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombocytopeniaD013921HP_0001873D69.6———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombosisD013927—1———1
Lung neoplasmsD008175C34.9011———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLEPIRUDIN
INNlepirudin
Description
Hirudin variant-1 (Lepirudin)
Classification
Protein
Drug classanticoagulants (hirudin type)
Image (chem structure or protein)LEPIRUDIN
Structure (InChI/SMILES or Protein Sequence)
>2ZFF:H|Thrombin heavy chain IVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISM LEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVL QVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFY THVFRLKKWIQKVIDQFGE >2ZFF:L|Thrombin light chain TFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGR
Identifiers
PDB1H8D, 1H8I, 1W7G, 2JOO, 2PW8, 2ZC9, 2ZDA, 2ZDV, 2ZF0, 2ZFF, 2ZFP, 2ZGB, 2ZGX, 2ZHQ, 2ZI2, 2ZIQ, 2ZNK, 2ZO3, 3D49, 3DHK, 3DT0, 3DUX, 3EGK, 3EQ0, 3LDX, 3UTU, 4AX9, 4BAH, 4BAK, 4BAM, 4BAN, 4BAQ, 4LXB, 4MLF, 4YES
CAS-ID138068-37-8
RxCUI237057
ChEMBL IDCHEMBL1201666
ChEBI ID—
PubChem CID—
DrugBankDB00001
UNII IDY43GF64R34 (ChemIDplus, GSRS)
Target
Agency Approved
F2
F2
Organism
Homo sapiens
Gene name
F2
Gene synonyms
NCBI Gene ID
2147
Protein name
prothrombin
Protein synonyms
Coagulation factor II, prepro-coagulation factor II, prothrombin B-chain, thrombin factor II
Uniprot ID
Q9UCA1
Mouse ortholog
F2 (14061)
prothrombin (P19221)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,081 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
301 adverse events reported
View more details